Literature DB >> 15202113

Technical and clinical evaluation of anti-ribosomal P protein immunoassays.

M Mahler1, K Kessenbrock, J Raats, M J Fritzler.   

Abstract

Autoantibodies to the three ribosomal phospho (-P) proteins P0, P1, P2, referred to as Rib-P, are specifically found in 10-40% of patients with systemic lupus erythematosus. The variations in the observed frequency of these autoantibodies is related to a number of factors such as the test system used to detect the antibodies. Several immunoassays that were designed for research and diagnostic laboratory use have been developed. The autoantigens employed in these tests include native proteins, recombinant polypeptides, and synthetic peptides. In this study, we compared the technical and clinical accuracy of anti-Rib-P antibody assays from different commercial suppliers including ELISA systems and a novel addressable laser bead assay (from Euroimmun, MBL, Pharmacia Diagnostics, INOVA). Although the assays from all suppliers used in this study performed well in the technical part of the study, relatively poor correlations and significant differences in the clinical accuracy were found. Based on the results, we conclude that the detection of anti-Rib-P antibodies strongly depends on both the nature of the antigen and the detection system. We recommend that anti-Rib-P assays should be standardized on an international level. The Varelisa Rib-P profile and the addressable laser bead Rib-P assays represent promising tools and platforms for the detection of anti-Rib-P antibodies in the future. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15202113      PMCID: PMC6807712          DOI: 10.1002/jcla.20026

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  30 in total

Review 1.  Proteomics technologies for the study of autoimmune disease.

Authors:  William H Robinson; Lawrence Steinman; Paul J Utz
Journal:  Arthritis Rheum       Date:  2002-04

2.  Antibodies to ribosomal P proteins and hepatic damage in undifferentiated CTD.

Authors:  J C Torre; L Mozo; A Suárez; E Ramos; C Gutiérrez
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

3.  Evaluation of assays for the detection of autoantibodies to the ribosomal P proteins.

Authors:  K Rayno; M Reichlin
Journal:  Clin Immunol       Date:  2000-05       Impact factor: 3.969

4.  Properties of the ribosomal P2 protein autoantigen are similar to those of foreign protein antigens.

Authors:  K Elkon; E Bonfa; R Llovet; W Danho; H Weissbach; N Brot
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

6.  Autoantibodies directed against ribosomal P proteins: use of a multiple antigen peptide as the coating agent in ELISA.

Authors:  L Caponi; S Pegoraro; V Di Bartolo; P Rovero; R Revoltella; S Bombardieri
Journal:  J Immunol Methods       Date:  1995-02-27       Impact factor: 2.303

7.  Comparison of five methods for the detection of antiribosomal P protein antibody.

Authors:  E Bonfa; N Gaburo Júnior; A V Tavares; W Cossermelli
Journal:  Braz J Med Biol Res       Date:  1994-03       Impact factor: 2.590

8.  Antiribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus.

Authors:  L S Teh; M K Lee; F Wang; M Manivasagar; P J Charles; G D Nicholson; E M Hay; D A Isenberg; N Amos; B D Williams
Journal:  Br J Rheumatol       Date:  1993-08

9.  Association between lupus psychosis and anti-ribosomal P protein antibodies.

Authors:  E Bonfa; S J Golombek; L D Kaufman; S Skelly; H Weissbach; N Brot; K B Elkon
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

10.  Classification criteria for polymyositis and dermatomyositis.

Authors:  K Tanimoto; K Nakano; S Kano; S Mori; H Ueki; H Nishitani; T Sato; T Kiuchi; Y Ohashi
Journal:  J Rheumatol       Date:  1995-04       Impact factor: 4.666

View more
  14 in total

1.  Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus.

Authors:  J L J Lin; V Dubljevic; M J Fritzler; Ban-Hock Toh
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

2.  International multicenter evaluation of autoantibodies to ribosomal P proteins.

Authors:  Michael Mahler; Kai Kessenbrock; Magdalena Szmyrka; Yoshinari Takasaki; Ignacio Garcia-De La Torre; Yehuda Shoenfeld; Falk Hiepe; Chen Shun-le; Carlos A von Mühlen; Henning Locht; Peter Höpfl; Allan Wiik; Westley Reeves; Marvin J Fritzler
Journal:  Clin Vaccine Immunol       Date:  2006-01

3.  Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope.

Authors:  M Mahler; N Agmon-Levin; M van Liempt; Y Shoenfeld; A Waka; F Hiepe; A Swart; I Gürtler; M J Fritzler
Journal:  Rheumatol Int       Date:  2010-12-08       Impact factor: 2.631

4.  Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay.

Authors:  M Mahler; L M Stinton; M J Fritzler
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

5.  The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV).

Authors:  Yufang Ding; Jiuliang Zhao; Junyan Qian; Li Zhang; Shangzhu Zhang; Nan Jiang; Jing Li; Chanyuan Wu; Qingjun Wu; Dong Xu; Xiaomei Leng; Qian Wang; Wen Zhang; Xinping Tian; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2022-01-27       Impact factor: 2.980

6.  Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection.

Authors:  K Kessenbrock; M J Fritzler; M Groves; P Eissfeller; C A von Mühlen; P Höpfl; M Mahler
Journal:  J Mol Med (Berl)       Date:  2007-08-01       Impact factor: 4.599

7.  Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus.

Authors:  Jing Li; Ying Shen; Jing He; Rulin Jia; Xiujie Wang; Xiaosan Chen; Dahai Wang; Lei Han; Lei Zhu; Xiaofeng Chi; Sandra Saschenbrecker; Cornelia Dähnrich; Winfried Stöcker; Wolfgang Schlumberger; Zhan-Guo Li
Journal:  J Clin Lab Anal       Date:  2013-02-11       Impact factor: 2.352

8.  Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Authors:  May Y Choi; Ann E Clarke; Yvan St Pierre; John G Hanly; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Ian N Bruce; Mary A Dooley; Paul R Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Graciela S Alarcón; Susan Manzi; Ola Nived; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Thomas Stoll; Jill Buyon; Michael Mahler; Marvin J Fritzler
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-06-12       Impact factor: 4.794

9.  Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies.

Authors:  Michael Mahler; Jennifer T Ngo; Johannes Schulte-Pelkum; Tanja Luettich; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2008-11-11       Impact factor: 5.156

10.  Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile.

Authors:  Diana Carmona-Fernandes; Maria José Santos; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.